GABAergic Function in Alzheimer's Disease: Evidence for Dysfunction and Potential as a Therapeutic Target for the Treatment of Behavioural and Psychological Symptoms of Dementia
Free accessResearch articleFirst published online July, 2004
GABAergic Function in Alzheimer's Disease: Evidence for Dysfunction and Potential as a Therapeutic Target for the Treatment of Behavioural and Psychological Symptoms of Dementia
Alzheimer's disease (AD) is characterized by disruptions in multiple major neurotransmitters. While many studies have attempted to establish whether GABA is disrupted in AD patients, findings have varied. We review evidence for disruptions in GABA among patients with AD and suggest that the variable findings reflect subtypes of the disease that are possibly manifested clinically by differing behavioural symptoms. GABA, the major inhibitory neurotransmitter, has long been a target for anxiolytics, hypnotic sedatives, and anticonvulsants. We review the clinical use of GABAergic agents in treating persons with AD symptoms. While newer generation GABAergic medications are now available, they have yet to be evaluated among patients with AD.
SmallGWRabinsPVBarryPPBuckholtzNSDeKoskySTFerrisSH, and others. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA1997;278:1363–71.
2.
Canadian Study of Health and Aging Working Group. Canadian Study of Health and Aging: Study methods and prevalence of dementia. Can Med Assoc J1994;150:899–913.
3.
DevanandDPJacobsDMTangMXDelCastillo-Castaneda CSanoMMarderK, and others. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry1997;54:257–63.
4.
CummingsJLBackC.The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry1998;6:S64–S78.
5.
HardyJAdolfssonRAlafuzoffIBuchtGMarcussonJNybergP, and others. Transmitter deficits in Alzheimer's disease. Neurochem Int1985;7:545–63.
6.
ReinikainenKJPaljarviLHuuskonenMSoininenHLaaksoMRiekkinenPJ. A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease. J Neurol Sci1988;84:101–16.
7.
LanctôtKLHerrmannNMazzottaP.Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci2001;13:5–21.
8.
WhitehousePJPriceDLClarkAWCoyleJTDeLongMR. Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol1981;10:122–6.
9.
CummingsJLKauferD.Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited. Neurology1996;47:876–83.
10.
IversenLLBloomFE. Studies of the uptake of 3H-GABA and (3H)glycine in slices and homogenates of rat brain and spinal cord by electron microscopic autoradiography. Brain Res1972;41:131–43.
11.
SivilottiLNistriA.GABA receptor mechanisms in the central nervous system. Prog Neurobiol1991;36:35–92.
12.
CurtisDRFelixDMcLellanH.GABA and hippocampal inhibition. Br J Pharmacol1970;40:881–3.
13.
StoreyEBealMF. Neurochemical substrates of rigidity and chorea in Huntington's disease. Brain1993;116:1201–22.
14.
NobregaJNRichterABurnhamW McIntyreLôscherW.Alterations in the brain GABAA/benzodiazepine receptor chloride ionophore complex in a genetic model of paroxysmal dystonia: A quantitative autoradiographic analysis. Neuroscience1995;64:229–39.
15.
PettyFTrivediMHFultonMRushAJ. Benzodiazepines as antidepressants: Does GABA play a role in depression?Biol Psychiatry1995;38:578–91.
16.
van KammenDPPettyFKelleyMEKramerGLBarryEJYaoJK, and others. GABA and brain abnormalities in schizophrenia. Psychiatry Res1998;82:25–35.
17.
KeverneEB. GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses. Brain Res Bull1999;48:467–73.
18.
EichelmanB.Neurochemical basis of aggressive behavior. Psychiatri Ann1987;17:371–4.
19.
AdamsDBBoudreauWCowanCWKokonowskiCOberteufferKYohayK.Offense produced by chemical stimulation of the anterior hypothalamus of the rat. Physiol Behav1993;53:1127–32.
20.
RoelingTAKrukMRSchuurmansRVeeningJG. Behavioural responses of bicucculline methiodide injections into the ventral hypothalamus of freely moving, socially interacting rats. Brain Res1993;615:121–7.
21.
PankseppJ.Drugs and stimulus-bound attack. Physiol Behav1971;6:317–20.
22.
FunderburkWHFoxwellMHHakalaMW. Effects of psychotherapeutic drugs on hypothalamic-induced hissing in cats. Neuropharmacology1970;9:1–7.
23.
MalickJBGoldbergME. Effects of a choline acetyltransferase inhibitor on self-stimulatory behavior in the rat. Arch Int Pharmacodyn Ther1970;184:252–6.
24.
DelgadoJMR. Antiaggressive effects of chlordiazepoxide. New York: Raven Press; 1973.
25.
DeckerMWMcGaughJL. The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse1991;7:151–68.
26.
ZorumskiCFIsenbergKE. Insights into the structure and function of GABA-benzodiazepine receptors: Ion channels and psychiatry. Am J Psychiatry1991;148:162–73.
27.
GuZZhongPYanZ.Activation of muscarinic receptors inhibits beta-amyloid peptide-induced signaling in cortical slices. J Biol Chem2003;278:17546–56.
28.
SherifFM. GABA-transaminase in brain and blood platelets: Basic and clinical aspects. Prog Neuropsychopharmacol Biol Psychiatry1994;18:1219–33.
29.
ChebibMJohnstonGA. The ‘ABC’ of GABA receptors: A brief review. Clin Exp Pharmacol Physiol1999;26:937–40.
30.
BormannJ.The ‘ABC’ of GABA receptors. Trends Pharmacol Sci2000;21:16–9.
31.
HowellOAtackJDewarDMcKernanMSurC.Density and Pharmacology of alpha-5 subunit-containing GABA A receptors are preserved in hippocampus of Alzheimer's disease. Neuroscience2000;98:669–75.
32.
SimpsonPBWoollacottAJPillaiGVMaubachKAHadinghamKLMartinK, and others. Pharmacology of recombinant human GABA(A) receptor subtypes measured using a novel pH-based high-throughput functional efficacy assay. J Neurosci Methods2000;99:91–100.
33.
McKernanRMRosahlTWReynoldsDSSurCWaffordKAAtackJR, and others. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype [comments]. Nat Neurosci2000;3:587–92.
34.
DobleA.New insights into the mechanism of action of hypnotics. J Psychopharmacol1999;13:S11–S20.
35.
ButterfieldAPocernichCB. The glutamatergic system and Alzheimer's disease. CNS Drugs2003;17:641–52.
36.
AbeSSuzukiTItoTBabaAHoriTKuritaH, and others. Differential expression of GABA(A) receptor subunit mRNAs and ligand binding sites in rat brain following phencyclidine administration. Synapse2000;38:51–60.
37.
LloydKMorselliP.Psychopharmacology of GABAergic drugs. In: MeltzerHMeltzerHS, editors. Psychopharmacology: The third generation of progress. New York: Raven Press; 1987. p 183–95.
38.
CooperJRBloomFERothRH. Amino acid transmitters. In: The biochemical basis of neuropharmacology. New York: Oxford University Press; 1996. p 126–93.
39.
YewDTLiWPWebbSELaiHWZhangL.Neurotransmitters, peptides, and neural cell adhesion molecules in the cortices of normal elderly humans and Alzheimer patients: A comparison. Exp Gerontol1999;34:117–33.
40.
MohanakrishnanPFowlerAHVonsattelJPHusainMMJollesPRLiemP, and others. An in vitro 1H nuclear magnetic resonance study of the temporoparietal cortex of Alzheimer brains. Exp Brain Res1995;102:503–10.
41.
PerryTLYongVWBergeronCHansenSJonesK.Amino acids, glutathione, and glutathione transferase activity in the brains of patients with Alzheimer's disease. Ann Neurol1987;21:331–6.
42.
LoweSLFrancisPTProcterAWPalmerAMDavisonANBowenDM. Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer's disease. Brain1988;111:785–99.
43.
SasakiHMuramotoOKanazawaIAraiHKosakaKIizukaR.Regional distribution of amino acid transmitters in postmortem brains of presenile and senile dementia of Alzheimer type. Ann Neurol1986;19:263–9.
44.
AraiHKobayashiKIchimiyaYKosakaKIizukaR.A preliminary study of free amino acids in the postmortem temporal cortex from Alzheimer-type dementia patients. Neurobiol Aging1984;5:319–21.
45.
RossorMNIversenLLReynoldsGPMountjoyCQRothM.Neurochemical characteristics of early and late onset types of Alzheimer's disease. BMJ (Clin Res Ed)1984;288:961–4.
46.
PerryEKAtackJRPerryRHHardyJADoddPREdwardsonJA, and others. Intralaminar neurochemical distributions in human midtemporal cortex: Comparison between Alzheimer's disease and the normal. J Neurochem1984;42:1402–10.
47.
EllisonDWBealMFMazurekMFBirdEDMartinJB. A postmortem study of amino acid neurotransmitters in Alzheimer's disease. Ann Neurol1986;20:616–21.
48.
RossorMNGarrettNJJohnsonALMountjoyCQRothMIversenLL. A post-mortem study of the cholinergic and GABA systems in senile dementia. Brain1982;105:313–30.
49.
TarbitIPerryEKPerryRHBlessedGTomlinsonBE. Hippocampal free amino acids in Alzheimer's disease. J Neurochem1980;35:1246–9.
50.
ProcterAWFrancisPTStratmannGCBowenDM. Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms. Neurochem Res1992;17:917–22.
51.
GreenamyreJTPenneyJBD'AmatoCJYoungAB. Dementia of the Alzheimer's type: Changes in hippocampal L-[3H]glutamate binding. J Neurochem1987;48:543–51.
52.
ShimohamaSTaniguchiTFujiwaraMKameyamaM.Changes in benzodiazepine receptors in Alzheimer-type dementia. Ann Neurol1988;23:404–6.
53.
JansenKLFaullRLDragunowMSynekBL. Alzheimer's disease: Changes in hippocampal N-methyl-D-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors an autoradiographic study. Neuroscience1990;39:613–27.
54.
CarlsonMDPenneyJBJrYoungAB. NMDA, AMPA, and benzodiazepine binding site changes in Alzheimer's disease visual cortex. Neurobiol Aging1993;14:343–52.
55.
CrossAJCrowTJFerrierINJohnsonJA. The selectivity of the reduction of serotonin S2 receptors in Alzheimer-type dementia. Neurobiol Aging1986;7:3–7.
56.
OwenFPoulterMWaddingtonJLMashalRDCrowTJ. [3H]R05–4864 and [3H]flunitrazepam binding in kainate-lesioned rat striatum and in temporal cortex of brains from patients with senile dementia of the Alzheimer type. Brain Res1983;278:373–5.
57.
SedvallGNybackHFardeLPerssonA.Neurotransmitter receptor imaging in Alzheimer's disease. J Neural Transm Suppl1987;24:43–8.
58.
GriffithsPDPerryRHCrossmanAR. A detailed anatomical analysis of neurotransmitter receptors in the putamen and caudate in Parkinson's disease and Alzheimer's disease. Neurosci Lett1994;169:68–72.
59.
SeidlRCairnsNSingewaldNKaehlerSTLubecG.Differences between GABA levels in Alzheiemer's disease and Down syndrome with Alzheimer-like neuropathology. Naunyn-Schmiedeberg's Arch Pharmacol2001;363:139–45.
60.
NäggaKBogdanovicNMarcussonJ.GABA transporters (GAT-1) in Alzheimer's disease. J Neural Transm1999;106:1141–9.
61.
ReisineTDYamamuraHIBirdEDSpokesEEnnaSJ. Pre- and postsynaptic neurochemical alterations in Alzheimer's disease. Brain Res1978;159:477–81.
62.
HardyJCowburnRBartonAReynoldsGDoddPWesterP and others. A disorder of cortical GABAergic innervation in Alzheimer's disease. Neurosci Lett1987;73:192–6.
63.
ChuDCPenneyJBJr.YoungAB. Quantitative autoradiography of hippocampal GABAB and GABAA receptor changes in Alzheimer's disease. Neurosci Lett1987;82:246–52.
64.
ChuDCPenneyJBJrYoungAB. Cortical GABAB and GABAA receptors in Alzheimer's disease: A quantitative autoradiographic study. Neurology1987;37:1454–9.
65.
VogtBACrinoPBVolicerL.Laminar alterations in gamma-aminobutyric acidA, muscarinic, and beta adrenoceptors and neuron degeneration in cingulate cortex in Alzheimer's disease. J Neurochem1991;57:282–90.
66.
PerryEKTomlinsonBEBlessedGBergmannKGibsonPHPerryRH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ1978;2:1457–9.
67.
DaviesP.Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res1979;171:319–27.
68.
NakamuraS.Senile dementia and presenile dementia. Tohoku J Exp Med1990;161(Suppl):49–60.
69.
YatesCMButterworthJTennantMCGordonA.Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias. J Neurochem1990;55:1624–30.
70.
BoissiereFFaucheuxBDuyckaertsCHauwJJAgidYHirschEC. Striatal expression of glutamic acid decarboxylase gene in Alzheimer's disease. J Neurochem1998;71:767–74.
71.
AoyagiTWadaTNagaiMKojimaFHaradaSTakeuchiT, and others. Increased gamma-aminobutyrate aminotransferase activity in brain of patients with Alzheimer's disease. Chem Pharm Bull (Tokyo)1990;38:1748–9.
72.
SherifFGottfriesCGAlafuzoffIOrelandL.Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer's disease. J Neural Transm Park Dis Dement Sect1992;4:227–40.
73.
SherifFAhmedSSErikssonL.Brain aminobutyrate aminotransferase activity in Alzheimer's disease [letter]. Neurodegeneration1995;4:114–5.
74.
SmithCCBowenDMSimsNRNearyDDavisonAN. Amino acid release from biopsy samples of temporal neocortex from patients with Alzheimer's disease. Brain Res1983;264:138–41.
75.
FosterNLVanDerSpekAFAldrichMSBerentSHichwaRHSackellaresJC, and others. The effect of diazepam sedation on cerebral glucose metabolism in Alzheimer's disease as measured using positron emission tomography. J Cereb Blood Flow Metab1987;7:415–20.
76.
FukuchiKHashikawaKSeikeYMoriwakiHOkuNIshidaM, and others. Comparison of iodine-123-iomazenil SPECT and technetium-99m-HMPAO-SPECT in Alzheimer's disease. J Nucl Med1997;38:467–70.
77.
MeyerMKoeppeRAFreyKAFosterNLKuhlDE. Positron emission tomography measures of benzodiazepine binding in Alzheimer's disease. Arch Neurol1995;52:314–7.
78.
OhyamaMSendaMIshiwataKKitamuraSMishinaMIshiiK, and others. Preserved benzodiazepine receptors in Alzheimer's disease measured with C-11 flumazenil PET and I-123 iomazenil SPECT in comparison with CBF. Ann Nucl Med1999;13:309–15.
79.
WyperDKellyCPattersonJ.Single photon emission computed tomography in Alzheimer's disease: A review of cerebral perfusion and acetylcholine muscarinic receptor imaging and a novel study of the GABA/benzodiazepine system. Inter J Geriatr Psychopharmacol1998;1:126–33.
80.
Jimenez-JimenezFJMolinaJAGomezPVargasCde BustosFBenito-LeonJ, and others. Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's disease. J Neural Transm1998;105:269–77.
81.
OishiMMochizukiYYoshihashiHTakasuTNakanoE.Laboratory examinations correlated with severity of dementia. Ann Clin Lab Sci1996;26:340–5.
82.
WeinerMFSpecialeSGRisserRCKramerGLPettyF.Cerebrospinal fluid and plasma gamma-aminobutyric acid in Alzheimer's disease. Biol Psychiatry1996;40:933–4.
83.
TohgiHAbeTTakahashiSKimuraM.A selective reduction of excitatory amino acids in cerebrospinal fluid of patients with Alzheimer type dementia compared with vascular dementia of the Binswanger type. Neurosci Lett1992;141:5–8.
84.
ToscaPCanevariLDi PaoloEFerrariRVerzeSZerbiF, and others. Glutamate and GABA levels in CSF from patients affected by dementia and olivo-ponto-cerebellar atrophy. Acta Neurol Scand1992;85:430–5.
85.
PomaraNDeptulaDGallowayMPLeWittPAStanleyM.CSF GABA in caregiver spouses of Alzheimer patients. Am J Psychiatry1989;146:787–8.
86.
KurodaH.Gamma-aminobutyric acid (GABA) in cerebrospinal fluid. Acta Med Okayama1983;37:167–77.
87.
BareggiSRFranceschiMBoniniLZeccaLSmirneS.Decreased CSF concentrations of homovanillic acid and gamma- aminobutyric acid in Alzheimer's disease. Age or disease-related modifications? Arch Neurol1982;39:709–12.
88.
MohrEBrunoGFosterNGillespieMCoxCHareTA, and others. GABA-agonist therapy for Alzheimer's disease. Clin Neuropharmacol1986;9:257–63.
89.
ZimmerRTeelkenAWTrielingWBWeberWWeihmayrTLauterH.Gamma-aminobutyric acid and homovanillic acid concentration in the CSF of patients with senile dementia of Alzheimer's type. Arch Neurol1984;41:602–4.
90.
ManyamNVKatzLHareTAGerberJCGrossmanMH. Levels of gamma-aminobutyric acid in cerebrospinal fluid in various neurologic disorders. Arch Neurol1980;37:352–5.
StahlSMMarkowitzJSGuttermanEMPapadopoulosG.Co-use of donepezil and hypnotics among Alzheimer's Disease patients living in the community. J Clin Psychiatry2003;64:466–72.
93.
AncillRJCarlyleWWLiangRAHollidaySG. Agitation in the demented elderly: A role for benzodiazepines?Int Clin Psychopharmacol1991;6:141–6.
94.
ChristensenDBBenfieldWR. Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients. J Am Geriatr Soc1998;46:620–5.
95.
SmeraskiPJ. Clonazepam treatment of multi-infarct dementia. J Geriatr Psychiatry Neurol1988;1:47–8.
96.
FreinharJPAlvarezWA. Clonazepam treatment of organic brain syndromes in three elderly patients. J Clin Psychiatry1986;47:525–6.
97.
GinsburgML. Clonazepam for agitated patients with Alzheimer's disease [letter]. Can J Psychiatry1991;36:237–8.
98.
CalkinPAKunikMEOrengoCAMolinariVWorkmanR.Tolerability of clonazepam in demented and non-demented geropsychiatric patients. Int J Geriatr Psychiatry1997;12:745–9.
99.
CovingtonJS. Alleviating agitation, apprehension, and related symptoms in geriatric patients: A double-blind comparison of a phenothiazine and a benzodiazepine. South Med J1975;68:719–24.
100.
KirvenLEMonteroEF. Comparison of thioridazine and diazepam in the control of nonpsychotic symptoms associated with senility: Double-blind study. J Am Geriatr Soc1973;21:546–51.
101.
ConnDKFergusonIMandelmanKWardC.Psychotropic drug utilization in long-term care facilities for the elderly in Ontario, Canada. Int Psychogeriatr1999;11:223–33.
102.
FritzJStewartJT. Lorazepam treatment of resistive aggression in dementia [letter]. Am J Psychiatry1990;147:1250.
103.
SunderlandTWeingartnerHCohenRMTariotPNNewhousePAThompsonKE, and others. Low-dose oral lorazepam administration in Alzheimer subjects and age- matched controls. Psychopharmacology (Berl)1989;99:129–33.
104.
MeehanKMWangHDavidSRNisivocciaJRJonesBBeasleyCMJr, and others. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: A double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacol2002;26:494–504.
105.
SandersJF. Evaluation of oxazepam and placebo in emotionally disturbed aged patients. Geriatrics1965;20:739–46.
106.
BeberCR. Management of behavior in the institutionalized aged. Dis Nerv Syst1965;26:591–5.
107.
ChesrowEJKaplitzSEVeltraHBremeJTMarquardtGH. Blind study of oxazepam in the management of geriatric patients with behaivoral problems. Clin Med1965;71:1001–5.
108.
CoccaroEFKramerEZemishlanyZThorneARiceCMGiordaniB, and others. Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. Am J Psychiatry1990;147:1640–5.
109.
HerzLRVolicerLRossVRheaumeY.A single-case-study method for treating resistiveness in patients with Alzheimer's disease. Hosp Community Psychiatry1992;43:720–4.
110.
SheltonPSHockingLB. Zolpidem for dementia-related insomnia and nighttime wandering. Ann Pharmacother1997;31:319–22.
111.
FastbomJForsellYWinbladB.Benzodiazepines may have protective effects against Alzheimer disease. Alzheimer Dis Assoc Disord1998;12:14–7.
112.
MarinDBGreenwaldBS. Carbamazepine for aggressive agitation in demented patients during nursing care [letter]. Am J Psychiatry1989;146:805.
113.
PattersonJF. Carbamazepine for assaultive patients with organic brain disease. Psychosomatics1987;28:579–81.
114.
PattersonJF. A preliminary study of carbamazepine in the treatment of assaultive patients with dementia. J Geriatr Psychiatry Neurol1988;1:21–3.
115.
LeiboviciATariotPN. Carbamazepine treatment of agitation associated with dementia. J Geriatr Psychiatry Neurol1988;1:110–2.
116.
EssaM.Carbamazepine in dementia. J Clin Psychopharmacol1986;6:234–6.
117.
AntonRFWaidLRFosseyMAuBuchonP.Case report of carbamazepine treatment of organic brain syndrome with psychotic features. J Clin Psychopharmacol1986;6:232–4.
118.
LemkeMR. Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics. J Clin Psychiatry1995;56:354–7.
119.
GleasonRPSchneiderLS. Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics [comments]. J Clin Psychiatry1990;51:115–8.
120.
TariotPNJakimovichLJErbRCoxCLanningBIrvineC, and others. Withdrawal from controlled carbamazepine therapy followed by further carbamazepine treatment in patients with dementia. J Clin Psychiatry1999;60:684–9.
121.
TariotPNErbRLeiboviciAPodgorskiCACoxCAsnisJ, and others. Carbamazepine treatment of agitation in nursing home patients with dementia: A preliminary study. J Am Geriatr Soc1994;42:1160–6.
122.
TariotPNErbRPodgorskiCACoxCPatelSJakimovichL, and others. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry1998;155:54–61.
123.
OlinJTFoxLSPawluczykSTaggartNASchneiderLS. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment resistant outpatients with Alzheimer's disease. Am J Geriatr Psychiatry2001;9:400–5.
124.
GuptaSO'ConnellRParekhAKrotzBStockwellD.Efficacy of valproate for agitation and aggression in dementia: Case reports. Int J Geriatr Psychopharmacol1998;1:244–8.
125.
SivalRCHaffmansPMvan GentPPvan NieuwkerkJF. The effects of sodium valproate on disturbed behavior in dementia [letter]. J Am Geriatr Soc1994;42:906–7.
126.
NarayanMNelsonJC. Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic. J Clin Psychiatry1997;58:351–4.
127.
FahsHPotironGSenonJLPerivierE.Anticonvulsants in agitation and behavior disorders in demented subjects: Report of 8 cases. Encephale1999;25:169–74.
128.
HerrmannN.Valproic acid treatment of agitation in dementia. Can J Psychiatry1998;43:69–72.
129.
HaasSVincentKHoltJLippmannS.Divalproex: A possible treatment alternative for demented, elderly aggressive patients. Ann Clin Psychiatry1997;9:145–7.
130.
PorsteinssonAPTariotPNErbRGaileS.An open trial of valproate for agitation in geriatric neuropsychiatric disorders. Am J Geriatr Psychiatry1997;5:344–51.
131.
HorneMLindleySE. Divalproex sodium in the treatment of aggressive behavior and dysphoria in patients with organic brain syndromes [letter]. J Clin Psychiatry1995;56:430–1.
132.
LottADMcElroySLKeysMA. Valproate in the treatment of behavioral agitation in elderly patients with dementia. J Neuropsychiatry Clin Neurosci1995;7:314–9.
133.
SandbornWDBendfeldtFHamdyR.Valproic acid for physically aggressive behaviour in geriatric patients. Am J Geriatr Psychiatry1995;3:239–42.
134.
MellowAMSolano-LopezCDavisS.Sodium valproate in the treatment of behavioral disturbance in dementia. J Geriatr Psychiatry Neurol1993;6:205–9.
135.
PorsteinssonAPTariotPNErbRCoxCSmithEJakimovichL, and others. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry2001;9:58–66.
136.
TariotPNSchneiderLSMintzerJECutlerAJCunninghamMThomasJ, and others. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: Results of a double-blind, placebo-controlled trial. Curr Ther Res Clin Exp2001;62:51–67.
137.
SivalRCHaffmansJJansenPAFDuursmaSAEikelenboomP.Sodium valproate in the treatment of aggressive behavior in patients with dementia-a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry2002;17:579–85.
138.
TrannelTJAhmedIGoebertD.Occurrence of thrombocytopenia in psychiatric patients taking valproate. Am J Psychiatry2001;158:128–30.
139.
SoCCWongKF. Valproate-associated dysmyelopoiesis in elderly patients. Am J Clin Pathol2002;118:225–8.
140.
HerrmannNLanctôtKMyszakM.Effectiveness of gabapentin for the treatment of behavioral disorders in dementia. J Clin Psychopharmacol2000;20:90–3.
141.
HawkinsJWTinklenbergJRSheikhJIPeyserCEYesavageJA. A retrospective chart review of gabapentin for the treatment of aggressive and agitated behavior in patients with dementias. Am J Geriatr Psychiatry2000;8:221–5.
142.
RoaneDMFeinbergTEMecklerLMinerCRScicutellaARosenthalRN. Treatment of dementia-associated agitation with gabapentin. J Neuropsychiatry Clin Neurosci2000;12:40–3.
143.
LowKCrestaniFKeistRBenkeDBrunigIBensonJA, and others. Molecular and neuronal substrate for the selective attenuation of anxiety. Science2000;290:131–4.
144.
RudolphUCrestaniFBenkeDBrunigIBensonJAFritschyJM, and others. Benzodiazepine actions mediated by specific gamma-aminobutyric acid (A) receptor subtypes. Nature1999;401:796–800.
145.
KardosJ.Recent advances in GABA research. Neurochem Int1999;34:353–8.
146.
VekovischevaOYHaapalinnaASarviharjuMHonkanenAKorpiER. Cerebellar GABA(A) receptors and anxiolytic action of diazepam. Brain Res1999;837:184–7.
